425 related articles for article (PubMed ID: 30678647)
21. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
22. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
23. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
25. C/EBPβ regulates the JAK/STAT signaling pathway in triple-negative breast cancer.
Wang S; Xia D; Wang X; Cao H; Wu C; Sun Z; Zhang D; Liu H
FEBS Open Bio; 2021 Apr; 11(4):1250-1258. PubMed ID: 33660927
[TBL] [Abstract][Full Text] [Related]
26. Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8
Kalimutho M; Sinha D; Mittal D; Srihari S; Nanayakkara D; Shafique S; Raninga P; Nag P; Parsons K; Khanna KK
J Exp Clin Cancer Res; 2019 Feb; 38(1):85. PubMed ID: 30777101
[TBL] [Abstract][Full Text] [Related]
27. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
30. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
31. Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances.
Arolla RG; Malladi S; Bhaduri U; Gayatri MB; Pattamshetty P; Mohan V; Katika MR; Madhava Reddy AB; Satyanarayana Rao MR; Vudem DR; Kancha RK
Biochem Biophys Res Commun; 2021 Jan; 534():461-467. PubMed ID: 33246559
[TBL] [Abstract][Full Text] [Related]
32. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
33. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
34. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells.
Tsui J; Qi S; Perrino S; Leibovitch M; Brodt P
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33916323
[TBL] [Abstract][Full Text] [Related]
35. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
36. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
37. Up-regulation of cathepsin S expression by HSP90 and 5-HT
Gautam J; Bae YK; Kim JA
Breast Cancer Res Treat; 2017 Jan; 161(1):29-40. PubMed ID: 27796714
[TBL] [Abstract][Full Text] [Related]
38. TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters.
Webb BM; Bryson BL; Williams-Medina E; Bobbitt JR; Seachrist DD; Anstine LJ; Keri RA
J Biol Chem; 2021 Oct; 297(4):101162. PubMed ID: 34481843
[TBL] [Abstract][Full Text] [Related]
39. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
40. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
